Prevalence and antimicrobial susceptibility data for extended-spectrum β-lactamase– and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997–2004)
- 16 December 2005
- journal article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 53 (4) , 257-264
- https://doi.org/10.1016/j.diagmicrobio.2005.10.001
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- CTX-M: changing the face of ESBLs in the UKJournal of Antimicrobial Chemotherapy, 2005
- The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in EuropeJournal of Antimicrobial Chemotherapy, 2005
- Pathogens resistant to antimicrobial agents: Epidemiology, molecular mechanisms, and clinical managementInfectious Disease Clinics of North America, 2004
- Results of two worldwide surveys into physician awareness and perceptions of extended-spectrum β-lactamasesClinical Microbiology & Infection, 2004
- Appropriate antimicrobial treatment in nosocomial infections—the clinical challengesJournal of Hospital Infection, 2003
- Antimicrobial Resistance in Gram-Negative Isolates from European Intensive Care Units: Data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) ProgrammeJournal of Chemotherapy, 2002
- Resistance Surveillance in Italy: Four-Year Results from the MYSTIC ProgramJournal of Chemotherapy, 2002
- Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f β-lactamase (SME-1) in the United States: results from the MYSTIC ProgrammeDiagnostic Microbiology and Infectious Disease, 2001
- Surveillance studies: how can they help the management of infection?Journal of Antimicrobial Chemotherapy, 2000
- Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997–1998Journal of Antimicrobial Chemotherapy, 2000